News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Grifols H1 Sales Meet Forecasts, Net Profit Misses
July 29, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Spain's Grifols (GRLS.MC), embroiled in a $3.4 billion takeover bid to become the world's third-largest haemoderivatives maker, posted a 3.7 percent rise in first-half sales, helped by strength at its Bioscience division.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Grifols
MORE ON THIS TOPIC
Collaboration
Crescent, Kelun-Biotech Swap Therapies in ADC-Bispecific Deal Worth Up To $1.25B
December 4, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Biotechs Secure Alternative Fill/Finish Capacity Amid Scrutiny of Novo Site
December 2, 2025
·
6 min read
·
Nick Paul Taylor
Series B
Novartis-Backed Protego Eyes Pivotal Amyloidosis Study With $130M Series B
December 1, 2025
·
1 min read
·
Tristan Manalac
Layoff Tracker
Valneva Terminates 30 Amid Site Closure
December 1, 2025
·
92 min read
·
BioSpace Editorial Staff